

### **Amendment to the Claims**

The following listing of claims will replace all prior versions and listings of claims.

#### **Listing of Claims:**

1. (Previously Presented) A process of screening compounds to identify antagonists of PSR comprising:
  - (a) combining a protein comprising a polypeptide having the amino acid sequence of SEQ ID NO:2, or active fragments thereof with a compound that forms a complex with the protein; and
  - (b) determining the ability of the compound to prevent the biological action of PSR.
- 2-5. (Canceled)
6. (Previously Presented) A process of screening compounds to identify antagonists of PSR comprising:
  - (a) combining a protein comprising a polypeptide having the amino acid sequence of SEQ ID NO:2, or active fragments thereof, with elements which undergo simultaneous oxidation and reduction in the presence of the compound to be screened under conditions where an oxidation reduction reaction normally takes place; and
  - (b) determining the ability of the compound to inhibit the reaction.
- 7-11. (Canceled)
12. (Previously Presented) A process of screening compounds to identify antagonists of PSR comprising:
  - (a) combining a protein comprising a polypeptide having the amino acid sequence of SEQ ID NO:2, or active fragments thereof in a competition assay, wherein the protein is contacted with a natural substrate for PSR and a compound; and
  - (b) determining the ability of the compound to compete with the natural substrate in a manner sufficient to prevent binding of PSR to said natural substrate.
- 13-40. (Canceled)
41. (New) A method of detecting PSR protein in a biological sample comprising:
  - (a) contacting the biological sample with an antibody or fragment thereof that specifically binds a protein consisting of amino acid residues 1 to 316 of SEQ ID NO:2; and

- (b) detecting said PSR protein in the biological sample bound to said antibody or fragment thereof.
42. (New) The method of claim 41 wherein the antibody or fragment thereof is a monoclonal antibody.
43. (New) The method of claim 41 wherein the antibody or fragment thereof is a polyclonal antibody.
44. (New) The method of claim 41 wherein the antibody or fragment thereof is selected from the group consisting of:
- (a) a chimeric antibody;
  - (b) a humanized antibody;
  - (c) a single chain antibody; and
  - (d) a Fab fragment.
45. (New) The method of claim 41 wherein the antibody or fragment thereof is labeled.
46. (New) The method of claim 45 wherein the label is selected from the group consisting of:
- (a) an enzyme label;
  - (b) a radioisotope;
  - (c) a fluorescent label; and
  - (d) a bioluminescent label.
47. (New) The method of claim 41 wherein the biological sample is tissue.
48. (New) The method of claim 41 wherein the biological sample is cells.
49. (New) The method of claim 41 wherein the biological sample is plasma.
50. (New) The method of claim 41 wherein the biological sample is serum.
51. (New) The method of claim 41 wherein the biological sample is saliva.

52. (New) The method of claim 41 wherein the biological sample is urine.
53. (New) A method of detecting PSR protein in a biological sample comprising:
- (a) contacting the biological sample with an antibody or fragment thereof that specifically binds a protein whose amino acid sequence consists of the mature polypeptide encoded by the cDNA contained in ATCC™ Deposit Number 75913; and
  - (b) detecting said PSR protein in the biological sample bound to said antibody or fragment thereof.
54. (New) The method of claim 53 wherein the antibody or fragment thereof is a monoclonal antibody.
55. (New) The method of claim 53 wherein the antibody or fragment thereof is a polyclonal antibody.
56. (New) The method of claim 53 wherein the antibody or fragment thereof is selected from the group consisting of:
- (a) a chimeric antibody;
  - (b) a humanized antibody;
  - (c) a single chain antibody; and
  - (d) a Fab fragment.
57. (New) The method of claim 53 wherein the antibody or fragment thereof is labeled.
58. (New) The method of claim 57 wherein the label is selected from the group consisting of:
- (a) an enzyme label;
  - (b) a radioisotope;
  - (c) a fluorescent label; and
  - (d) a bioluminescent label.

59. (New) The method of claim 53 wherein the biological sample is tissue.
60. (New) The method of claim 53 wherein the biological sample is cells.
61. (New) The method of claim 53 wherein the biological sample is plasma.
62. (New) The method of claim 53 wherein the biological sample is serum.
63. (New) The method of claim 53 wherein the biological sample is saliva.
64. (New) The method of claim 53 wherein the biological sample is urine.